EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun iD, Brian M Maas iD, Mickie H Cheng iD, S Aubrey Stoch iD, Haiyan Li iD

Clinical and Translational Science · 2026-04 · 19 (4)

DOI: 10.1111/cts.70481 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 29.03.2026. Verfasst von Jixiang Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Clinical Trials Center, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Cytidine, Hydroxylamines. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation. An open‐label, fixed‐sequence, Phase 1 study was conducted to evaluate the tolerability, safety, and pharmacokinetics (PK) following single and multiple (every 12 h for 5.5 days) oral dosing of molnupiravir 800 mg in 16 healthy, male Chinese participants. After multiple doses of molnupiravir, the median time to maximum concentration was 2.0 h for plasma NHC. NHC concentrations generally decreased in a biphasic manner, with a terminal half‐life of 21.9 h, and NHC exposures (i.e., area under the curve and maximum plasma concentration) were similar following single and multiple doses of molnupiravir. No accumulation of NHC in plasma was observed. When compared with historical data from published clinical trials of similar study design, NHC exposure in Chinese participants was marginally higher than that in non‐Asian participants but remained within established clinical bounds. Overall, molnupiravir was generally well‐tolerated. Ten participants (63.5%) experienced at least one adverse event throughout the study, the severity of which was mild or moderate, and none led to treatment discontinuation. There were no clinically meaningful findings in other safety evaluations. These data support use of the standard 5‐day regimen of molnupiravir 800 mg every 12 h without dose adjustment for the treatment of COVID‐19 in the Chinese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentCytidineHydroxylaminesAdultHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveChinaCOVID-19Drug Administration ScheduleHealthy VolunteersEast Asian People

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2antiviralphase 1ribonucleoside analogβ‐D‐N4‐hydroxycytidine

Substanzen

Antiviral AgentsCytidineHydroxylaminesmolnupiravir

Autor:innen und Institutionen

  • Department of Drug Clinical Trials Center, Peking University Third Hospital, Beijing, China.
  • MSD China, Beijing, China.
  • MSD China, Shanghai, China.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
  • Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Fang Sun, Brian M Maas, Mickie H Cheng, S Aubrey Stoch, Haiyan Li

Zitieren

APA

Zhu, J., Zhang, D., Liu, Z., Yan, B., Zang, Y., Zhao, W., Sun, F., Maas, B. M., Cheng, M. H., Stoch, S. A., & Li, H. (2026). Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study. Clinical and Translational Science, 19(4). https://doi.org/10.1111/cts.70481

Vancouver

Zhu J, Zhang D, Liu Z, Yan B, Zang Y, Zhao W, et al. Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study. Clinical and Translational Science. 2026;19(4). doi:10.1111/cts.70481

BibTeX
@article{Zhu2026,
  author = {Zhu, Jixiang and Zhang, Danning and Liu, Zhiping and Yan, Bei and Zang, Yanqiao and Zhao, Weiwei and Sun, Fang and Maas, Brian M and Cheng, Mickie H and Stoch, S Aubrey and Li, Haiyan},
  title = {Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {4},
  doi = {10.1111/cts.70481}
}
Kostenlos starten →